According to a study conducted by Banaras Hindu University, those who have been cured of coronavirus require only one dosage of vaccine.
New Delhi: According to a study conducted by five scientists from Banaras Hindu University, one dosage of Coronavirus vaccination is adequate for persons who have been infected with the virus once. Let us know that patients are currently being given two doses of the Corona Vaccine.
In ten days, sufficient antibodies are produced.
For patients who have recovered from Corona illness, the initial dose of Corona Vaccine creates adequate antibodies within 10 days. These antibodies have been shown to be effective in the battle against corona. After immunization, those coronas that have not been infected take 3 to 4 weeks to produce antibodies.
PM Modi received advice from scientists.
In a letter to Prime Minister Narendra Modi, scientists propose that only one dosage of Corona Vaccine be required for patients who have recovered from Corona. This will also help to alleviate the vaccine shortage by allowing more people to receive vaccines on schedule.
What are the lecturers at BHU studying?
A pilot study of 20 participants was conducted by professors at Banaras Hindu University. Natural antibodies were studied for their role and advantages. Antibodies were generated quickly in persons healing from corona, according to the study, and it only required 10 days. Antibodies were produced in normal subjects in 21 to 28 days after receiving both doses.
4 important aspects of BHU research
1. After recovering from corona, one dose of vaccine is sufficient.
2. Those healing from corona produce antibodies after ten days.
3. Antibodies will be produced after 3-4 weeks of both dosages if the corona is not present.
4. The corona has been removed. Antibodies might last for several months.
Who was a part of the BHU study?
Department of Neurology, Prof. VN Mishra
Department of Neurology Professor Abhishek Pathak
Prof. Gyaneshwar Chaubey, Department of Zoology Department of Zoology’s Prajwal Singh
Zoology Department’s Pranab Gupta
This research will have two advantages.
Antibody disappears in a few months, which is concerning. The second point of concern is that vaccine manufacturers’ production capacity is restricted. This research, on the other hand, will offer two advantages. Priority will be given to the application of the first vaccine. That is, it will be able to choose who receives the vaccine first. Before patients who have recovered from Corona may be given the Corona Vaccine, which has not yet been corona, they must first recover from Corona. The second benefit is that even if firms restrict manufacturing, the vaccine will still be available to everyone.